This company is the first to investigate DMT as a treatment for stroke - BNN Bloomberg

{{data.symbol | reutersRICLabelFormat:group.RICS}}

{{data.netChng | number: 4 }}

{{data.netChng | number: 2 }}

{{data | displayCurrencySymbol}} {{data.price | number: 4 }}

{{data.price | number: 2 }}

{{data.symbol | reutersRICLabelFormat:group.RICS}}

{{data.netChng | number: 4 }}

{{data.netChng | number: 2 }}

{{data | displayCurrencySymbol}} {{data.price | number: 4 }}

{{data.price | number: 2 }}

Markets

As of: {{timeStamp.date}}
{{timeStamp.time}}

{{ stock.symbol }} {{ stock.price | currency }} {{ stock | formatPrefix }}{{ stock.netChng | formatNetChange }}

LIVE:
Watch BNN Bloomberg, Canada's Business News Network, live here now

Investment Trends

This company is the first to investigate DMT as a treatment for stroke

Market One Media Group

This company is the first to investigate DMT as a treatment for stroke

VIDEO SIGN OUT

After being granted permission to conduct a Phase 1 study for the treatment of stroke, Algernon Pharmaceuticals is establishing itself as a biotech powerhouse

Markets

BNN

Scoreboard

BNN

LIVE:

Investment Trends

{{ currentStream.Name }}

Related Video

This company is the first to investigate DMT as a treatment for stroke

This company is the first to investigate DMT as a treatment for stroke